Abstract
Introduction Preclinical studies demonstrate the potential of amylin in the diagnosis of Alzheimer's disease (AD). We aimed to lay the foundation for repurposing the amylin analog and a diabetes drug, pramlintide, for AD in humans. Methods We administered a single subcutaneous injection of 60 μg of pramlintide to nondiabetic subjects under fasting conditions. Results None of the participants developed hypoglycemia after the injection of pramlintide. The pramlintide challenge induced a significant surge of amyloid-β peptide and a decrease in total tau in the plasma of AD subjects but not in control participants. The pramlintide injection provoked an increase in interleukin 1 receptor antagonist and a decrease in retinol-binding protein 4, which separates AD subjects from control subjects. Discussion Pramlintide use appeared to be safe in the absence of diabetes. The biomarker changes as a result of the pramlintide challenge, which distinguished AD from control subjects and mild cognitive impairment.
Original language | English (US) |
---|---|
Pages (from-to) | 33-43 |
Number of pages | 11 |
Journal | Alzheimer's and Dementia: Translational Research and Clinical Interventions |
Volume | 3 |
Issue number | 1 |
DOIs | |
State | Published - Jan 1 2017 |
Keywords
- Alzheimer's disease (AD)
- Amylin challenge
- Biomarkers
- Diagnosis
- Pramlintide
- Safety
ASJC Scopus subject areas
- Clinical Neurology
- Psychiatry and Mental health